$SRTS
Sensus Healthcare, Inc. Stock $srts

$srts Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000121390023022355 Filed on March 23, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022
Revenue	$3.414M	$13.11M	$44.53M
YoY Change	-66.98%	0.61%	64.68%
Cost Of Revenue	$1.792M	$4.754M	$14.90M
YoY Change	-43.81%	14.03%	48.24%
Gross Profit	$1.622M	$8.351M	$29.63M
YoY Change	-77.31%	-5.7%	74.41%
Gross Profit Margin	47.51%	63.72%	66.53%
Selling, General & Admin	$3.463M	$3.020M	$11.34M
YoY Change	39.02%	24.23%	20.2%
% of Gross Profit	213.5%	36.16%	38.26%
Research & Development	$1.098M	$1.158M	$3.460M
YoY Change	50.82%	4.7%	0.7%
% of Gross Profit	67.69%	13.87%	11.68%
Depreciation & Amortization	$73.00K	$74.00K	$315.0K
YoY Change	-20.65%	-47.52%	-48.61%
% of Gross Profit	4.5%	0.89%	1.06%
Operating Expenses	$4.561M	$4.178M	$14.80M
YoY Change	41.69%	18.12%	14.99%
Operating Profit	-$2.939M	$4.173M	$14.83M
YoY Change	-174.78%	-21.55%	259.98%
Interest Expense	-$243.0K	$235.0K	$380.0K
YoY Change	-24400.0%
% of Operating Profit		5.63%	2.56%
Other Income/Expense, Net	$243.0K		$13.16M
YoY Change	-98.1%		-1316000.0%
Pretax Income	-$2.696M	$4.408M	$27.99M
YoY Change	-116.13%	-17.11%	579.53%
Income Tax	-$802.0K	$1.577M	$3.746M
% Of Pretax Income		35.78%	13.38%
Net Earnings	-$1.894M	$2.831M	$24.24M
YoY Change	-111.79%	-46.77%	488.59%
Net Earnings / Revenue	-55.48%	21.6%	54.44%
Basic Earnings Per Share	-$0.12		$1.47
Diluted Earnings Per Share	-$0.12	$0.17	$1.46
COMMON SHARES
Basic Shares Outstanding	16.40M shares	16.61M shares	16.48M shares
Diluted Shares Outstanding	16.25M shares		16.62M shares

Balance Sheet

Concept	2023 Q1	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$19.34M	$25.52M	$25.52M
YoY Change	-41.09%	75.77%	75.77%
Cash & Equivalents	$19.34M	$25.52M	$25.52M
Short-Term Investments
Other Short-Term Assets	$10.65M	$7.389M	$7.389M
YoY Change	285.18%	160.45%	160.45%
Inventory	$6.342M	$3.501M	$3.501M
Prepaid Expenses		$6.261M
Receivables	$12.73M	$17.30M	$17.30M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$49.07M	$53.71M	$53.71M
YoY Change	1.25%	71.9%	71.9%
LONG-TERM ASSETS
Property, Plant & Equipment	$397.0K	$1.239M	$1.239M
YoY Change	-74.62%	104.79%	60.08%
Goodwill
YoY Change
Intangibles	$25.00K	$50.00K
YoY Change		-65.75%
Long-Term Investments
YoY Change
Other Assets	$419.0K	$1.737M	$1.737M
YoY Change	-88.92%	2216.0%	2216.0%
Total Long-Term Assets	$4.329M	$3.026M	$3.026M
YoY Change	-20.82%	204.12%	204.12%
TOTAL ASSETS
Total Short-Term Assets	$49.07M	$53.71M	$53.71M
Total Long-Term Assets	$4.329M	$3.026M	$3.026M
Total Assets	$53.40M	$56.74M	$56.74M
YoY Change	-0.98%	75.98%	75.98%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.928M	$5.521M	$5.521M
YoY Change	11.54%	36.05%	36.05%
Accrued Expenses	$192.0K	$190.0K	$190.0K
YoY Change	3.78%	9.2%	9.2%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due		$0.00	$0.00
YoY Change		-100.0%	-100.0%
Total Short-Term Liabilities	$6.166M	$7.697M	$7.697M
YoY Change	-39.91%	29.08%	29.08%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$908.0K	$969.0K	$969.0K
YoY Change	-24.9%	269.85%	269.85%
Total Long-Term Liabilities	$908.0K	$969.0K	$969.0K
YoY Change	-24.9%	269.85%	269.85%
TOTAL LIABILITIES
Total Short-Term Liabilities	$6.166M	$7.697M	$7.697M
Total Long-Term Liabilities	$908.0K	$969.0K	$969.0K
Total Liabilities	$7.074M	$8.666M	$8.666M
YoY Change	-38.33%	39.21%	39.21%
SHAREHOLDERS EQUITY
Retained Earnings	$4.408M	$6.302M
YoY Change		-135.12%
Common Stock	$45.39M	$45.20M
YoY Change		2.07%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$3.473M	$3.433M
YoY Change		956.31%
Treasury Stock Shares		10.10K shares
Shareholders Equity	$46.32M	$48.07M	$48.07M
YoY Change
Total Liabilities & Shareholders Equity	$53.40M	$56.74M	$56.74M
YoY Change	-0.98%	75.98%	75.98%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	-$1.894M	$2.831M	$24.24M
YoY Change	-111.79%	-46.77%	488.59%
Depreciation, Depletion And Amortization	$73.00K	$74.00K	$315.0K
YoY Change	-20.65%	-47.52%	-48.61%
Cash From Operating Activities	-$5.997M	-$10.11M	-$1.412M
YoY Change	-294.58%	468.15%	393.71%
INVESTING ACTIVITIES
Capital Expenditures	$189.0K	$10.00K	$159.0K
YoY Change	-529.55%	-126.32%	-224.22%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	$15.00M
YoY Change	-100.0%		5736.58%
Cash From Investing Activities	-$189.0K	-$10.00K	$14.84M
YoY Change	-101.26%	-73.68%	11404.65%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$6.000K	-1.934M	-$2.428M
YoY Change	-97.8%	3481.48%	951.08%
NET CHANGE
Cash From Operating Activities	-$5.997M	-10.11M	-$1.412M
Cash From Investing Activities	-$189.0K	-10.00K	$14.84M
Cash From Financing Activities	$6.000K	-1.934M	-$2.428M
Net Change In Cash	-$6.180M	-12.06M	$11.00M
YoY Change	-133.75%	544.07%	-2935.31%
FREE CASH FLOW
Cash From Operating Activities	-$5.997M	-$10.11M	-$1.412M
Capital Expenditures	$189.0K	$10.00K	$159.0K
Free Cash Flow	-$6.186M	-$10.12M	-$1.571M
YoY Change	-297.89%	481.11%	894.3%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	001-37714
CY2022	dei	Entity Registrant Name EntityRegistrantName	Sensus Healthcare, Inc.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	27-1647271
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	851 Broken Sound Pkwy
CY2022	dei	Entity Address Address Line2 EntityAddressAddressLine2	NW #215, Boca Raton
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Florida
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	33487
CY2022	dei	City Area Code CityAreaCode	(561)
CY2022	dei	Local Phone Number LocalPhoneNumber	922-5808
CY2022	dei	Security12b Title Security12bTitle	Common Stock, par value $0.01 per share
CY2022	dei	Trading Symbol TradingSymbol	SRTS
CY2022	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	113764116	usd
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	16396766	shares
CY2022	dei	Auditor Name AuditorName	Marcum llp
CY2022	dei	Auditor Location AuditorLocation	Fort Lauderdale, FL.
CY2022	dei	Auditor Firm AuditorFirmId	688
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	25520000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	14519000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	17299000	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	12130000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	3501000	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	1759000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	6921000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2837000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	53241000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	31245000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	243000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	605000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	50000	usd
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	146000	usd
CY2022Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	24000	usd
CY2021Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	75000	usd
CY2022Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	1713000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	996000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	169000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	468000	usd
CY2022Q4	us-gaap	Assets Assets	56735000	usd
CY2021Q4	us-gaap	Assets Assets	32240000	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	5521000	usd
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	4058000	usd
CY2022Q4	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	403000	usd
CY2021Q4	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	508000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	190000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	174000	usd
CY2021Q4	us-gaap	Loans Payable Current LoansPayableCurrent	51000	usd
CY2022Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	890000	usd
CY2022Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	693000	usd
CY2021Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1172000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	7697000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	5963000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	830000	usd
CY2022Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	139000	usd
CY2021Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	262000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	8666000	usd
CY2021Q4	us-gaap	Liabilities Liabilities	6225000	usd
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	16902761	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	16390419	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	16694311	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	16617274	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	169000	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	167000	usd
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	45031000	usd
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	44115000	usd
CY2022Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	512342	shares
CY2021Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	77037	shares
CY2022Q4	us-gaap	Treasury Stock Value TreasuryStockValue	3433000	usd
CY2021Q4	us-gaap	Treasury Stock Value TreasuryStockValue	325000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	6302000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-17942000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	48069000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	26015000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	56735000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	32240000	usd
CY2022	us-gaap	Revenues Revenues	44532000	usd
CY2021	us-gaap	Revenues Revenues	27042000	usd
CY2022	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	14904000	usd
CY2021	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	10054000	usd
CY2022	us-gaap	Gross Profit GrossProfit	29628000	usd
CY2021	us-gaap	Gross Profit GrossProfit	16988000	usd
CY2022	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	6329000	usd
CY2021	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	4838000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5008000	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4594000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3460000	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3436000	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	14797000	usd
CY2021	us-gaap	Operating Expenses OperatingExpenses	12868000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	14831000	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	4120000	usd
CY2022	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	12779000	usd
CY2021	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-1000	usd
CY2022	us-gaap	Interest Income Other InterestIncomeOther	382000	usd
CY2021	us-gaap	Interest Income Other InterestIncomeOther	2000	usd
CY2022	us-gaap	Interest Expense InterestExpense	2000	usd
CY2021	us-gaap	Interest Expense InterestExpense	2000	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	13159000	usd
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	27990000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	4119000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	3746000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	24244000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	4119000	usd
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.47
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.25
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.46
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.25
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	16480991	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	16476122	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	16618214	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	16503134	shares
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	21496000	usd
CY2021	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	415000	usd
CY2021	srts	Surrender Of Shares For Tax Withholding On Stock Compensation SurrenderOfSharesForTaxWithholdingOnStockCompensation	-15000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	4119000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	26015000	usd
CY2022	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	187000	usd
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	731000	usd
CY2022	us-gaap	Stock Redeemed Or Called During Period Value StockRedeemedOrCalledDuringPeriodValue	-2999000	usd
CY2022	srts	Surrender Of Shares For Tax Withholding On Stock Compensation SurrenderOfSharesForTaxWithholdingOnStockCompensation	-109000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	24244000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	48069000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	24244000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	4119000	usd
CY2022	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	145000	usd
CY2021	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	78000	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	315000	usd
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	613000	usd
CY2021	srts	Loss On Sale Of Property And Equipment LossOnSaleOfPropertyAndEquipment	47000	usd
CY2022	us-gaap	Gain Loss On Sale Of Properties GainLossOnSaleOfProperties	12779000	usd
CY2022	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-197000	usd
CY2021	us-gaap	Gain Loss On Termination Of Lease GainLossOnTerminationOfLease	38000	usd
CY2022	srts	Provision For Product Warranties ProvisionForProductWarranties	-722000	usd
CY2021	srts	Provision For Product Warranties ProvisionForProductWarranties	-530000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	187000	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	415000	usd
CY2021	us-gaap	Asset Impairment Charges AssetImpairmentCharges	88000	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-1713000	usd
CY2022	srts	Accounts Receivable AccountsReceivable	-5314000	usd
CY2021	srts	Accounts Receivable AccountsReceivable	-8432000	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	3191000	usd
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-2735000	usd
CY2022	us-gaap	Increase Decrease In Security Deposits IncreaseDecreaseInSecurityDeposits	51000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	3869000	usd
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	557000	usd
CY2022	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	468000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	799000	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	962000	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-199000	usd
CY2022	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	890000	usd
CY2022	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-602000	usd
CY2021	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-637000	usd
CY2022	srts	Product Warranties ProductWarranties	827000	usd
CY2021	srts	Product Warranties ProductWarranties	209000	usd
CY2022	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	-25656000	usd
CY2021	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	-4405000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1412000	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-286000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	159000	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	128000	usd
CY2022	us-gaap	Proceeds From Sale Of Other Assets Investing Activities ProceedsFromSaleOfOtherAssetsInvestingActivities	15000000	usd
CY2021	us-gaap	Proceeds From Sale Of Other Assets Investing Activities ProceedsFromSaleOfOtherAssetsInvestingActivities	257000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	14841000	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	129000	usd
CY2022	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	2999000	usd
CY2022	srts	Withholding Taxes On Stock Compensations WithholdingTaxesOnStockCompensations	109000	usd
CY2021	srts	Withholding Taxes On Stock Compensations WithholdingTaxesOnStockCompensations	15000	usd
CY2022	srts	Paymentsfor Proceedsfrom Loanpayable PaymentsforProceedsfromLoanpayable	51000	usd
CY2021	srts	Paymentsfor Proceedsfrom Loanpayable PaymentsforProceedsfromLoanpayable	216000	usd
CY2022	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	731000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-2428000	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-231000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	11001000	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-388000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	14519000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	14907000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	25520000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	14519000	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	2000	usd
CY2021	us-gaap	Interest Paid Net InterestPaidNet	2000	usd
CY2022	us-gaap	Income Taxes Paid IncomeTaxesPaid	4570000	usd
CY2022	srts	Lease Liabilities Arising From Obtaining Rightofuseassets LeaseLiabilitiesArisingFromObtainingRightofuseassets	1045000	usd
CY2021	srts	Decrease In Operating Lease Rightofuse Asset And Operating Lease Liabilities DecreaseInOperatingLeaseRightofuseAssetAndOperatingLeaseLiabilities	655000	usd
CY2022	srts	Ppp Loanforgiveness Portions PPPLoanforgivenessPortions	-48000	usd
CY2021	srts	Ppp Loanforgiveness Portions PPPLoanforgivenessPortions	-66000	usd
CY2022	us-gaap	Nature Of Operations NatureOfOperations	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-variant: small-caps"><b><i>Description of the Business</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Sensus Healthcare, Inc. (together, with its subsidiary, unless the context otherwise indicates, “Sensus” or the “Company”) is a manufacturer of radiation therapy devices and sells the devices to healthcare providers globally through its distribution and marketing network. The Company operates as one segment from its corporate headquarters located in Boca Raton, Florida.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2022	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	pure
CY2022	us-gaap	Line Of Credit Facility Description LineOfCreditFacilityDescription	The Company has had a revolving credit facility with SVB that, as of December 31, 2021, provided for maximum borrowings equal to the lesser of (a) the $10 million commitment amount or (b) the borrowing base plus a $3 million non-formula sublimit. In April 2022, the term was extended to April 1, 2024, and the maximum borrowings were increased to the lesser of (a) the $15 million commitment amount or (b) the borrowing base plus a $7.5 million non-formula sublimit.
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-variant: small-caps"><b><i>Use of Estimates</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-variant: small-caps"><b><i> </i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, including disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expense during the reporting periods. Actual results could differ from those estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2020Q4	us-gaap	Deferred Revenue DeferredRevenue	2071000	usd
CY2021	us-gaap	Deferred Revenue Revenue Recognized1 DeferredRevenueRevenueRecognized1	3136000	usd
CY2021	srts	Amounts Invoiced AmountsInvoiced	2499000	usd
CY2021Q4	us-gaap	Deferred Revenue DeferredRevenue	1434000	usd
CY2022	us-gaap	Deferred Revenue Revenue Recognized1 DeferredRevenueRevenueRecognized1	4189000	usd
CY2022	srts	Amounts Invoiced AmountsInvoiced	3587000	usd
CY2022Q4	us-gaap	Deferred Revenue DeferredRevenue	832000	usd
CY2022Q4	srts	Estimated Service Revenue Obligation Due In Third Year EstimatedServiceRevenueObligationDueInThirdYear	648000	usd
CY2022Q4	srts	Estimated Service Revenue Obligation Due In Fourth Year EstimatedServiceRevenueObligationDueInFourthYear	96000	usd
CY2022Q4	srts	Estimated Service Revenue Obligation Due In Five Year EstimatedServiceRevenueObligationDueInFiveYear	23000	usd
CY2022Q4	srts	Estimated Service Revenue Obligation Due In Six Year EstimatedServiceRevenueObligationDueInSixYear	20000	usd
CY2022Q4	srts	Estimated Service Revenue Obligation Due EstimatedServiceRevenueObligationDue	787000	usd
CY2022	srts	Revenue Term Year RevenueTermYear	P1Y
CY2022Q4	us-gaap	Other Borrowings OtherBorrowings	15000000	usd
CY2022	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-variant: small-caps"><b><i>Concentration</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial instruments that potentially subject the Company to concentration of credit risk consist primarily of cash and cash equivalents and accounts receivable.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 10, 2023, Silicon Valley Bank (“SVB”) was closed by California and federal regulatory agencies. As a result of these actions, the FDIC established Silicon Valley Bridge Bank (the “Bridge Bank”). Based upon information available to us, we believe that the Bridge Bank has assumed all contracts SVB entered into prior to its failure, that the Bridge Bank is expected to continue to perform under those contracts, and that all counterparties are consequently expected to perform under those contracts.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">One customer in the U.S. accounted for approximately 73% and 57% of revenue for the years ended December 31, 2022 and 2021, respectively, and 91% and 94% of the accounts receivable as of December 31, 2022 and 2021, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2022	srts	Number Of Customer NumberOfCustomer	1	pure
CY2022Q4	us-gaap	Revenue Remaining Performance Obligation Percentage RevenueRemainingPerformanceObligationPercentage	0.73	pure
CY2021Q4	us-gaap	Revenue Remaining Performance Obligation Percentage RevenueRemainingPerformanceObligationPercentage	0.57	pure
CY2022	srts	Accounts Receivable Percentage AccountsReceivablePercentage	0.91	pure
CY2021	srts	Accounts Receivable Percentage AccountsReceivablePercentage	0.94	pure
CY2022	srts	Total Revenue TotalRevenue	44532000	usd
CY2022	srts	Total Revenue Percentage TotalRevenuePercentage	1	pure
CY2021	srts	Total Revenue TotalRevenue	27042000	usd
CY2021	srts	Total Revenue Percentage TotalRevenuePercentage	1	pure
CY2022	us-gaap	Line Of Credit Facility Borrowing Capacity Description LineOfCreditFacilityBorrowingCapacityDescription	Interest on any borrowings, at Prime plus 0.75% (8.25% at December 31, 2022) and Prime plus 1.50% on non-formula borrowings (9% at December 31, 2022) is payable monthly, and the outstanding principal and interest are due on the maturity date.
CY2022	us-gaap	Line Of Credit Facility Unused Capacity Commitment Fee Percentage LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage	0.0025	pure
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	107000	usd
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	69000	usd
CY2022Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	145000	usd
CY2021Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	78000	usd
CY2022Q4	us-gaap	Deposit Assets DepositAssets	6337000	usd
CY2021Q4	us-gaap	Deposit Assets DepositAssets	2529000	usd
CY2022Q4	us-gaap	Prepaid Insurance PrepaidInsurance	46000	usd
CY2021Q4	us-gaap	Prepaid Insurance PrepaidInsurance	40000	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	538000	usd
CY2021Q4	us-gaap	Other Assets Current OtherAssetsCurrent	268000	usd
CY2022Q4	us-gaap	Other Assets OtherAssets	6921000	usd
CY2021Q4	us-gaap	Other Assets OtherAssets	2837000	usd
CY2020Q2	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	1022785	usd
CY2022Q2	us-gaap	Debt Instrument Maturity Date Description DebtInstrumentMaturityDateDescription	The loan matured in April 2022 and provided for interest at the rate of 1% per annum.
CY2020	us-gaap	Line Of Credit Facility Decrease Forgiveness1 LineOfCreditFacilityDecreaseForgiveness1	757782	usd
CY2022Q4	us-gaap	Other Inventory OtherInventory	48000	usd
CY2021Q4	us-gaap	Other Inventory OtherInventory	66000	usd
CY2022	us-gaap	Other Asset Impairment Charges OtherAssetImpairmentCharges	0	usd
CY2021	us-gaap	Other Asset Impairment Charges OtherAssetImpairmentCharges	88000	usd
CY2022	us-gaap	Other Selling And Marketing Expense OtherSellingAndMarketingExpense	871	usd
CY2021	us-gaap	Other Selling And Marketing Expense OtherSellingAndMarketingExpense	460000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2374000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2816000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2131000	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2211000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	243000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	605000	usd
CY2021Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	257000	usd
CY2021	srts	Impairment Of Intangible Asset Finite Lived ImpairmentOfIntangibleAssetFiniteLived	88000	usd
CY2021	us-gaap	Proceeds From Sale Of Other Property Plant And Equipment ProceedsFromSaleOfOtherPropertyPlantAndEquipment	47000	usd
CY2022Q1	us-gaap	Disposal Group Including Discontinued Operation Other Current Assets DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets	15000000	usd
CY2022Q4	us-gaap	Cash Cash	15000000	usd
CY2022Q4	us-gaap	Inventory Gross InventoryGross	1401000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	157000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	663000	usd
CY2022	srts	Gain On Asset Sale GainOnAssetSale	12779000	usd
CY2022	us-gaap	Depreciation Expense On Reclassified Assets DepreciationExpenseOnReclassifiedAssets	219000	usd
CY2021	us-gaap	Depreciation Expense On Reclassified Assets DepreciationExpenseOnReclassifiedAssets	509000	usd
CY2022Q4	us-gaap	Property Subject To Or Available For Operating Lease Accumulated Depreciation PropertySubjectToOrAvailableForOperatingLeaseAccumulatedDepreciation	435000	usd
CY2021Q4	us-gaap	Property Subject To Or Available For Operating Lease Accumulated Depreciation PropertySubjectToOrAvailableForOperatingLeaseAccumulatedDepreciation	88000	usd
CY2022Q4	us-gaap	Forward Contract Indexed To Equity Settlement Share Fair Value Per Share ForwardContractIndexedToEquitySettlementShareFairValuePerShare	6.4
CY2020Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	338000	usd
CY2021	us-gaap	Asset Impairment Charges AssetImpairmentCharges	88000	usd
CY2021	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	104000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	146000	usd
CY2022	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	96000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	50000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	96000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	104000	usd
CY2022	us-gaap	Present Value Of Future Insurance Profits Weighted Average Amortization Period PresentValueOfFutureInsuranceProfitsWeightedAverageAmortizationPeriod	P0Y8M12D
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	49000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	1000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	50000	usd
CY2020Q4	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	187000	usd
CY2021	us-gaap	Product Warranty Accrual Warranties Issued ProductWarrantyAccrualWarrantiesIssued	530000	usd
CY2021	us-gaap	Product Warranty Accrual Payments ProductWarrantyAccrualPayments	209000	usd
CY2021Q4	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	508000	usd
CY2022	us-gaap	Product Warranty Accrual Warranties Issued ProductWarrantyAccrualWarrantiesIssued	722000	usd
CY2022	us-gaap	Product Warranty Accrual Payments ProductWarrantyAccrualPayments	827000	usd
CY2022Q4	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	403000	usd
CY2022	srts	Lessee Operating Leases Liability To Be Paid LesseeOperatingLeasesLiabilityToBePaid	1156000	usd
CY2022	us-gaap	Subordinated Borrowing Interest Rate SubordinatedBorrowingInterestRate	0.05	pure
CY2022	us-gaap	Adjustment For Amortization AdjustmentForAmortization	194000	usd
CY2021	us-gaap	Adjustment For Amortization AdjustmentForAmortization	208000	usd
CY2022Q4	srts	Operating Leases Future Minimum Payments Due2022 OperatingLeasesFutureMinimumPaymentsDue2022	221000	usd
CY2022Q4	srts	Operating Leases Future Minimum Payment Due In Two Years OperatingLeasesFutureMinimumPaymentDueInTwoYears	238000	usd
CY2022Q4	srts	Operating Leases Future Minimum Payment Due In Three Years OperatingLeasesFutureMinimumPaymentDueInThreeYears	245000	usd
CY2022Q4	srts	Operating Leases Future Minimum Payment Due In Four Years OperatingLeasesFutureMinimumPaymentDueInFourYears	253000	usd
CY2022Q4	srts	Operating Leases Future Minimum Payment Due In Five Years OperatingLeasesFutureMinimumPaymentDueInFiveYears	194000	usd
CY2022Q4	srts	Operating Leases Future Minimum Payments Due Total Undiscounted Operating Leases Payments OperatingLeasesFutureMinimumPaymentsDueTotalUndiscountedOperatingLeasesPayments	1151000	usd
CY2022Q4	srts	Operating Lease Imputed Interest OperatingLeaseImputedInterest	131000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	1020000	usd
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y9M
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.05	pure
CY2022	us-gaap	Increase Decrease In Operating Liabilities IncreaseDecreaseInOperatingLiabilities	199000	usd
CY2021	us-gaap	Increase Decrease In Operating Liabilities IncreaseDecreaseInOperatingLiabilities	331000	usd
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	255000	usd
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	335000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P10Y
CY2022Q4	srts	Restricted Vest Percentage RestrictedVestPercentage	0.25	pure
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	97884	shares
CY2022	us-gaap	Payments For Proceeds From Productive Assets PaymentsForProceedsFromProductiveAssets	22900000	usd
CY2021	us-gaap	Payments For Proceeds From Productive Assets PaymentsForProceedsFromProductiveAssets	5900000	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current And Noncurrent AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent	1500000	usd
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current And Noncurrent AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent	1200000	usd
CY2022	us-gaap	Other Labor Related Expenses OtherLaborRelatedExpenses	95000	usd
CY2021	us-gaap	Other Labor Related Expenses OtherLaborRelatedExpenses	98000	usd
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2022Q4	us-gaap	Excess Stock Shares Issued ExcessStockSharesIssued	131450	shares
CY2022	us-gaap	Stock Option Exercise Price Decrease StockOptionExercisePriceDecrease	5.55
CY2022Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	10096	shares
CY2022	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	425209	shares
CY2022	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	3000000	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	58973	shares
CY2020Q1	us-gaap	Stock Issued During Period Shares Restricted Stock Award Gross StockIssuedDuringPeriodSharesRestrictedStockAwardGross	35000	shares
CY2020Q1	us-gaap	Forward Contract Indexed To Equity Settlement Share Fair Value Per Share ForwardContractIndexedToEquitySettlementShareFairValuePerShare	4.11
CY2020Q1	srts	Restricted Vest Percentage RestrictedVestPercentage	0.25	pure
CY2021Q3	us-gaap	Stock Issued During Period Shares Restricted Stock Award Gross StockIssuedDuringPeriodSharesRestrictedStockAwardGross	130000	shares
CY2021Q3	us-gaap	Forward Contract Indexed To Equity Settlement Share Fair Value Per Share ForwardContractIndexedToEquitySettlementShareFairValuePerShare	3.84
CY2021Q3	srts	Restricted Vest Percentage RestrictedVestPercentage	0.25	pure
CY2021Q3	srts	Restricted Grant Percentage RestrictedGrantPercentage	0.25	pure
CY2022Q4	us-gaap	Stock Issued During Period Shares Restricted Stock Award Gross StockIssuedDuringPeriodSharesRestrictedStockAwardGross	77000	shares
CY2022	srts	Weighted Average Remaining Contractual Term In Years Granted WeightedAverageRemainingContractualTermInYearsGranted
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	37500	shares
CY2020Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	4.17
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	130000	shares
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	3.84
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	43750	shares
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	3.96
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	123750	shares
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	3.9
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	77000	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	6.4
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	41250	shares
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	3.9
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	159500	shares
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	5.11
CY2022	us-gaap	Stock Issued During Period Value Share Based Compensation Forfeited StockIssuedDuringPeriodValueShareBasedCompensationForfeited	0	usd
CY2021	us-gaap	Stock Issued During Period Value Share Based Compensation Forfeited StockIssuedDuringPeriodValueShareBasedCompensationForfeited	0	usd
CY2022	us-gaap	Unrecognized Tax Benefits Interest On Income Taxes Expense UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense	709000	usd
CY2022	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P3Y1M13D
CY2022	srts	Stock Options Expire Grant Date StockOptionsExpireGrantDate	P10Y
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	229334	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.55
CY2020Q4	srts	Sharebased Compensation Arrangement By Sharebased Payments Award Options Outstanding Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentsAwardOptionsOutstandingWeightedAverageRemainingContractualTerm	P7Y25D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	229334	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.55
CY2021Q4	srts	Sharebased Compensation Arrangement By Sharebased Payments Award Options Outstanding Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentsAwardOptionsOutstandingWeightedAverageRemainingContractualTerm	P6Y25D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	229334	shares
CY2021Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1	5.55
CY2021	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P6Y25D
CY2022	srts	Number Of Options Exercised NumberOfOptionsExercised	-131450	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	5.55
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	97884	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.55
CY2022Q4	srts	Sharebased Compensation Arrangement By Sharebased Payments Award Options Outstanding Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentsAwardOptionsOutstandingWeightedAverageRemainingContractualTerm	P5Y29D
CY2022Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1	5.55
CY2022	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P5Y29D
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised Net Of Tax Benefit Expense StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense	183000	usd
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised Net Of Tax Benefit Expense StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense	382000	usd
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	561000	usd
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	0	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount	791000	usd
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount	0	usd
CY2022	us-gaap	Restricted Stock Expense RestrictedStockExpense	187000	usd
CY2021	us-gaap	Restricted Stock Expense RestrictedStockExpense	415000	usd
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	2977000	usd
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	2482000	usd
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	2218000	usd
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-854000	usd
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-369000	usd
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-236000	usd
CY2022	srts	Deferred International Income Tax Expense Benefit DeferredInternationalIncomeTaxExpenseBenefit	-55000	usd
CY2021	srts	Deferred International Income Tax Expense Benefit DeferredInternationalIncomeTaxExpenseBenefit	-15000	usd
CY2022	us-gaap	Other Tax Expense Benefit OtherTaxExpenseBenefit	7253000	usd
CY2021	us-gaap	Other Tax Expense Benefit OtherTaxExpenseBenefit	-1105000	usd
CY2022	us-gaap	Servicing Asset At Amortized Value Valuation Allowance ServicingAssetAtAmortizedValueValuationAllowance	-3507000	usd
CY2021	us-gaap	Servicing Asset At Amortized Value Valuation Allowance ServicingAssetAtAmortizedValueValuationAllowance	1105000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	3746000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.073	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.049	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.004	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0.001	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	-0.011	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.009	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.009	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.001	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.125	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.268	pure
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.134	pure
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	849000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	2336000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	117000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	274000	usd
CY2022Q4	srts	Deferred Tax Assets Depreciation And Amortization DeferredTaxAssetsDepreciationAndAmortization	209000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	404000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	240000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	35000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	183000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	290000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	750000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Charitable Contribution Carryforwards DeferredTaxAssetsCharitableContributionCarryforwards	26000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts	6000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts	2000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	2000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	1910000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	3813000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	185000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	3692000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	1725000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	121000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	12000	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	11000	usd
CY2021Q4	us-gaap	Deferred Tax And Other Liabilities Noncurrent DeferredTaxAndOtherLiabilitiesNoncurrent	110000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	12000	usd
CY2021Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	121000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	1713000	usd
CY2022	us-gaap	Income Tax Holiday Aggregate Dollar Amount IncomeTaxHolidayAggregateDollarAmount	7700000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	340000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Not Subject To Expiration DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration	766000	usd
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	3500000	usd
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	1100000	usd
CY2021Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet		usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent		usd
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding		shares
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022	srts	Loss On Sale Of Property And Equipment LossOnSaleOfPropertyAndEquipment		usd
CY2021	us-gaap	Gain Loss On Sale Of Properties GainLossOnSaleOfProperties		usd
CY2021	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1		usd
CY2022	us-gaap	Gain Loss On Termination Of Lease GainLossOnTerminationOfLease		usd
CY2022	us-gaap	Asset Impairment Charges AssetImpairmentCharges		usd
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit		usd
CY2021	us-gaap	Increase Decrease In Security Deposits IncreaseDecreaseInSecurityDeposits		usd
CY2021	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets		usd
CY2021	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability		usd
CY2021	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock		usd
CY2021	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises		usd
CY2021	us-gaap	Income Taxes Paid IncomeTaxesPaid		usd
CY2021	srts	Lease Liabilities Arising From Obtaining Rightofuseassets LeaseLiabilitiesArisingFromObtainingRightofuseassets		usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo		usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree		usd
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding		shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding		shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod		shares
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod		shares
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross		shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2021	srts	Weighted Average Remaining Contractual Term In Years Granted WeightedAverageRemainingContractualTermInYearsGranted
CY2021	srts	Number Of Options Exercised NumberOfOptionsExercised		shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2021	srts	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercised Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedOutstandingWeightedAverageRemainingContractualTerm2
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod		shares
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
CY2021	srts	Weighted Average Remaining Contractual Term In Years Expired WeightedAverageRemainingContractualTermInYearsExpired
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross		shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2022	srts	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercised Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedOutstandingWeightedAverageRemainingContractualTerm2
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod		shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
CY2022	srts	Weighted Average Remaining Contractual Term In Years Expired WeightedAverageRemainingContractualTermInYearsExpired
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit		usd
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit		usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2021Q4	srts	Deferred Tax Assets Depreciation And Amortization DeferredTaxAssetsDepreciationAndAmortization		usd
CY2022Q4	us-gaap	Deferred Tax Assets Charitable Contribution Carryforwards DeferredTaxAssetsCharitableContributionCarryforwards		usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2022Q4	us-gaap	Deferred Tax And Other Liabilities Noncurrent DeferredTaxAndOtherLiabilitiesNoncurrent		usd
CY2021Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities		usd
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001494891

Files In Submission

Name	View Source	Status
0001213900-23-022355-index-headers.html	Edgar Link	pending
0001213900-23-022355-index.html	Edgar Link	pending
0001213900-23-022355.txt	Edgar Link	pending
0001213900-23-022355-xbrl.zip	Edgar Link	pending
f10k2022ex23-1_sensus.htm	Edgar Link	pending
f10k2022ex31-1_sensus.htm	Edgar Link	pending
f10k2022ex31-2_sensus.htm	Edgar Link	pending
f10k2022ex32-1_sensus.htm	Edgar Link	pending
f10k2022ex32-2_sensus.htm	Edgar Link	pending
f10k2022_sensushealth.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
image_001.jpg	Edgar Link	pending
image_002.jpg	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
f10k2022_sensushealth_htm.xml	Edgar Link	completed
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
srts-20221231.xsd	Edgar Link	pending
srts-20221231_cal.xml	Edgar Link	unprocessable
srts-20221231_def.xml	Edgar Link	unprocessable
srts-20221231_lab.xml	Edgar Link	unprocessable
srts-20221231_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SRTS
Sensus Healthcare, Inc. Stock $srts

2023 Q1 Form 10-K Financial Statement

#000121390023022355 Filed on March 23, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SRTS Sensus Healthcare, Inc. Stock $srts

2023 Q1 Form 10-K Financial Statement

#000121390023022355 Filed on March 23, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SRTS
Sensus Healthcare, Inc. Stock $srts